The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia. The antibiotic, Xenleta, received priority review under an FDA Safety and Innovation Act designation for drug products intended to treat serious or life-threatening infections. About 1 million people are hospitalized with community-acquired pneumonia annually in the United States. “For managing this serious disease, it is important for physicians and patients to have treatment options,” said Ed Cox, M.D., director of FDA’s Office of Antimicrobial Products. “This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics.”  
 

Related News Articles

Headline
The Department of Health and Human Services yesterday announced the reestablishment of the Ready Reserve Corps, a uniformed services that provides trained and…
Headline
The Centers for Disease Control and Prevention yesterday issued a health advisory warning of an uptick over the last year in meningococcal disease in which…
Headline
Loyola Medicine has maintained a strong partnership with its neighboring communities in Chicago’s near western suburbs. Prior to the COVID-19 pandemic, this…
Headline
Each June “What Matters to You?” Day aims to encourage meaningful conversations between people who provide and receive health and social care. The AHA will…
Chairperson's File
June 5 is the fourth annual Hospitals Against Violence Hope (#HAVhope) Friday. This year’s national day of awareness, which is taking place as protests against…
Headline
During Community Health Improvement Week, the AHA is sharing stories, resources, tools and leadership blogs that reflect on the importance of community and…